Trans Genic Receives Japanese Patents on Knockout Mice for Drug Development
Last Updated on Wednesday, 5 October 2005 03:12 Written by admin Wednesday, 5 October 2005 03:12
By Bruce Porter, JCN Staff Writer
Tokyo (JCN) – Trans Genic has announced that its patents on genetically modified (“knockout”) mice are now registered by the Japan Patent Office (Japanese Patent No. 371167 and 3713513). In collaboration with Kumamoto University, the Japan Science and Technology Agency and EU GENE, which was absorbed by Trans Genic as of July 1, the company filed application for patents for the mice.
Trans Genic expects that the knockout mice will play a role in the process of screening and assessing candidate compounds for neovascularization with the aim of contributing to drug development.
Trans Genic has announced that its patents on genetically modified (“knockout”) mice are now registered by the Japan Patent Office (Japanese Patent No. 371167 and 3713513). In collaboration with Kumamoto University, the Japan Science and Technology Agency and EU GENE, which was absorbed by Trans Genic as of July 1, the company filed application for patents for the mice.
Trans Genic expects that the knockout mice will play a role in the process of screening and assessing candidate compounds for neovascularization with the aim of contributing to drug development.
Main Menu
- Home
- About Bioscreening.net
- Glossary
- Biotechnology Glossary A-I
- Biotechnology Glossary J-Q
- Biotechnology Glossary R-Z
- Bird Flu
- Cheminformatic Glossary
- Endotoxins
- Fullerenes
- Genipin
- Gossypol (Gossipol)
- Grants, Venture Capital, and Government Funding
- High-throughput screening
- Lipinski Rule-of-Five
- Mumie
- Natural Medicine
- Rule-of-Three (Ro3)
- Targeted Libraries
- Web Directory